simvastatin has been researched along with Cancer of Cervix in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ma, L; Pan, Q; Xu, J | 1 |
| Brañes, J; Carvajal, J; Chen-Lin, K; Cuello, M; Gejman, R; Kato, S; Oliva, B; Owen, GI; Sadarangani, A; Smalley, S | 1 |
2 other study(ies) available for simvastatin and Cancer of Cervix
| Article | Year |
|---|---|
Simvastatin enhances chemotherapy in cervical cancer via inhibition of multiple prenylation-dependent GTPases-regulated pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; GTP Phosphohydrolases; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice, SCID; Paclitaxel; Polyisoprenyl Phosphates; Protein Prenylation; Simvastatin; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelium; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Mevalonic Acid; Ovarian Neoplasms; Polyisoprenyl Phosphates; Pravastatin; Sesquiterpenes; Signal Transduction; Simvastatin; Uterine Cervical Neoplasms; Water | 2010 |